Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Supplement labels can look professional and official, but they often hide critical information that dementia caregivers need to know. The FDA does not require pre-approval of dietary supplements before they’re sold to the public, and it does not verify the claims companies make about cognitive benefits or brain health. What you read on a bottle of ginkgo biloba, vitamin B12, coconut oil, or any other supplement marketed for memory and thinking is often incomplete—sometimes dangerously so. A caregiver might read that a supplement contains “natural ingredients” and assume it’s been rigorously tested for safety and efficacy, when in reality the FDA only requires five basic label statements: the name of the product, the amount inside, basic nutrition information, an ingredient list, and the manufacturer’s address. Everything else—including whether it actually works, whether it’s safe for someone taking blood thinners, or whether it could be contaminated—is largely the responsibility of the manufacturer to verify.
For someone with dementia, incomplete supplement labels carry real consequences. Not a single food, beverage, vitamin, or supplement has been proven to prevent, treat, or cure Alzheimer’s disease or slow cognitive decline. Yet caregivers often give supplements hoping they’ll help, sometimes without realizing that what the label promises and what the product can actually deliver are two very different things. Some manufacturers even intentionally hide drug ingredients from labels to avoid FDA scrutiny—for example, weight loss supplements sold as “all-natural” have been found to contain sibutramine, a weight loss drug banned by the FDA. When you’re caring for someone with dementia, a hidden ingredient can mean hidden danger.
Table of Contents
- Why Supplement Labels Fall Short: What the FDA Doesn’t Require
- The Missing Safety Information: Drug Interactions and Overdose Risks
- No Evidence of Brain Benefits: What Labels Claim vs. What Science Shows
- What Caregivers Should Know Before Giving Supplements
- Hidden Dangers Beyond the Label
- The Caregiver Communication Gap
- Emerging Regulatory Changes and What’s Next
- Conclusion
Why Supplement Labels Fall Short: What the FDA Doesn’t Require
The FDA’s oversight of supplements is fundamentally different from its regulation of prescription medications. With drugs, manufacturers must prove safety and efficacy before a product reaches the market. With supplements, there is no such requirement. A company can manufacture a product, slap a label on it, and sell it tomorrow without FDA approval. The agency only steps in after a product is already for sale if there’s evidence of harm. This reactive approach means caregivers are essentially the first line of safety testing—they’re giving untested products to vulnerable people. When the FDA does require supplement companies to include information on labels, it’s surprisingly minimal.
Beyond the five mandatory statements, there’s no requirement that companies warn about drug interactions, list potential side effects, or even clearly state that the supplement has not been proven to work. A label can claim a supplement “supports cognitive function” or “promotes brain health” without any evidence backing these assertions. The company must use careful language—they cannot claim the product “treats” or “cures” dementia—but words like “supports” and “promotes” create an illusion of benefit without accountability. This gap between what labels must say and what caregivers need to know is particularly dangerous because many dementia caregivers are under stress and may not have time to research each supplement independently. They trust the label to be honest. They assume that if something is on a shelf at a health food store or pharmacy, someone has verified it’s safe and works. That assumption is false.
The Missing Safety Information: Drug Interactions and Overdose Risks
The single most dangerous piece of information missing from supplement labels is interaction data with prescription medications. Studies have found that 11 to 56 percent of supplement users with dementia experience interactions between the supplements they take and their prescription drugs. These interactions can reduce the effectiveness of medications, increase side effects, or create new health risks entirely. A caregiver might give a supplement to help with memory while unknowingly increasing the risk of bleeding if the person is also taking a blood thinner, or reducing the effectiveness of depression medication if they’re taking St. John’s Wort. None of this information is on the label. Overdose is another risk labels fail to address.
Individuals with dementia are at high risk of taking supplements twice because they forget they’ve already taken a dose. Unlike prescription medications, where many caregivers supervise administration, only 36 percent of dementia patients receive caregiver assistance with supplements, compared to 73 percent who receive help with prescription medications. This means most people with dementia are managing their own supplements without supervision, despite the cognitive impairment that could lead to dangerous repetition. A label that says “take once daily” doesn’t account for memory loss—it assumes the person taking it will remember whether they took it an hour ago or yesterday. Documented cases show that supplements can cause serious harm: liver and kidney dysfunction, abnormal bleeding, and even fatal outcomes in people with dementia. Yet caregivers reading labels typically see only the ingredient list, not warnings about these real risks. The label doesn’t tell you that the supplement sitting on your shelf has been linked to liver injury or that it interacts with 15 different prescription drugs.
No Evidence of Brain Benefits: What Labels Claim vs. What Science Shows
Walking through any health food store, you’ll find dozens of supplements marketed specifically for memory, focus, brain health, and cognitive decline. Ginkgo biloba has been sold for decades with claims about sharpening mental clarity. Turmeric and curcumin are promoted as anti-inflammatory agents for the brain. Coconut oil is marketed as a brain fuel. B vitamins, especially B12, are heavily promoted for cognitive function in older adults.
Yet the reality, according to the Alzheimer’s Association, is stark: not one of these supplements has been proven to prevent, treat, or cure Alzheimer’s disease or benefit cognitive function. This gap between marketing and evidence is perhaps the most fundamental way that supplement labels mislead caregivers. The label doesn’t say “no evidence of benefit.” It says something like “supports healthy cognitive function” or “promotes brain wellness,” language that deliberately avoids making a claim that would require proof, while still creating an impression of benefit. A caregiver might spend money on expensive supplements, believing they’re doing everything possible to help, when that money could be directed toward proven interventions: staying physically active, maintaining social connections, managing blood pressure, controlling diabetes, or engaging in cognitive stimulation activities that actually have evidence behind them. The lack of efficacy evidence is especially important because caregivers often give supplements instead of pursuing these proven strategies, or they delay medical evaluation hoping a supplement will help. Meanwhile, the person with dementia isn’t getting the care interventions that could actually make a difference.
What Caregivers Should Know Before Giving Supplements
Before giving any supplement to someone with dementia, a caregiver should do what the label won’t: talk to the person’s doctor or pharmacist about every single supplement, including over-the-counter vitamins and herbal products. This is not optional. The doctor needs to know because they understand the person’s medications, medical conditions, and specific health risks in a way that a label never can. Yet nearly 50 percent of caregivers who sought advice from healthcare professionals about supplement use reported dissatisfaction with the response. Some doctors dismissed their questions. Others didn’t ask thorough follow-up questions. This communication gap means caregivers are often left to make decisions without adequate professional guidance. A caregiver should compare what the label claims against what actual research shows.
If a label says a supplement “supports memory,” that caregiver should ask: What does the research actually say? Has this been studied in people with dementia? Or is it just studied in healthy volunteers? Did the studies show a meaningful difference, or a tiny statistical difference that doesn’t translate to real-world benefit? These questions are almost never answered by reading the label alone. They require research, and they require conversations with healthcare providers who specialize in dementia care. Finally, caregivers should understand that “natural” on a label means nothing. Natural ingredients can be toxic. Arsenic is natural. Lead is natural. A supplement made from botanical ingredients is not automatically safer than a pharmaceutical. In fact, botanical supplements can vary wildly in their concentration of active compounds depending on when and where the plant was harvested, how it was processed, and how long it’s been sitting on a shelf. One bottle of ginkgo biloba might contain twice the active ingredient of another bottle from a different manufacturer, even though both labels look identical.
Hidden Dangers Beyond the Label
Some manufacturers intentionally omit ingredients from labels to avoid FDA scrutiny. If a supplement contains an undisclosed pharmaceutical ingredient—like a banned weight loss drug added to a “natural” diet supplement—the label won’t tell you because the company is hiding it. The FDA has documented cases where weight loss products marketed as all-natural contained sibutramine, a pharmaceutical that was banned precisely because of safety concerns. A caregiver giving such a supplement is exposing the person with dementia to an unapproved drug without knowing it. Contamination is another hidden danger. Third-party testing services can test supplements for quality and purity, but this testing is not required, and the results are not printed on the label. A supplement bottle might contain heavy metals, bacteria, or completely different ingredients than what the label lists.
A caregiver buying supplements at a discount store or from an unfamiliar online retailer has no way to know whether the product has been tested for contamination. The label doesn’t say anything about it. Storage and shelf life also pose risks that labels downplay. Many supplements lose potency over time, especially if they’re stored in warm or humid conditions. A bottle that’s been sitting on a drugstore shelf in direct sunlight for months might contain much less of the active ingredient than when it was manufactured. The label lists the amount at manufacture, not what’s actually in the bottle when the caregiver opens it at home. For someone with dementia taking multiple supplements, this unpredictability compounds the risk.
The Caregiver Communication Gap
When caregivers do try to get professional advice about supplements, they often find that doctors and pharmacists don’t ask detailed questions about supplement use, and caregivers don’t always volunteer the information. This communication failure means that healthcare providers don’t have a complete picture of what the person with dementia is actually taking. A drug interaction that could have been caught in a conversation never gets discussed. Caregivers report frustration when they ask healthcare providers about supplements and receive vague answers like “it probably won’t hurt” or dismissive responses that don’t take their concerns seriously. This dissatisfaction pushes caregivers toward self-directed supplement decisions, relying entirely on what they read on labels.
The medical community’s knowledge gap compounds the problem. Many doctors have limited training in supplement-drug interactions or the evidence (or lack thereof) for supplements in dementia. A caregiver asking a busy primary care doctor about ginkgo biloba might not get an informed answer. This is why pharmacy consultation is especially important—pharmacists have detailed knowledge of interactions and can often provide better guidance than a doctor who sees the person briefly. But even this resource is underutilized, and the label itself never suggests that a caregiver should consult a pharmacist before use.
Emerging Regulatory Changes and What’s Next
The FDA is tightening supplement oversight. As of 2025, the agency’s Human Foods Program is implementing stricter import and allergen standards for supplements. Enhanced import requirements mean that supplements coming from overseas will face closer scrutiny before reaching the U.S. market, though labels won’t reflect this change. New allergen labeling standards will also require manufacturers to disclose more information about potential allergens, which matters for caregivers managing someone with dementia who might have allergies they’ve forgotten or can’t communicate.
Looking ahead to 2026, the FDA may eliminate the current GRAS (Generally Recognized as Safe) self-affirmation process and require manufacturers to notify the agency before introducing new ingredients to the market. This would represent a significant shift—currently, companies can declare an ingredient GRAS on their own authority without FDA approval. The new rules might require prior notification before U.S. market placement, which could mean better safety evaluation before products reach shelves. However, these changes are still under review, and it’s unclear whether they’ll be implemented as proposed. Even if they are, they won’t retroactively apply to supplements already on the market, and labels won’t be required to highlight that a supplement was approved under old, less stringent standards.
Conclusion
Supplement labels are designed to meet regulatory requirements, not to inform caregivers about everything they need to know. They don’t disclose whether a supplement works, which drugs it might interact with, whether it’s been tested for contamination, or whether it’s appropriate for someone with memory loss who might forget whether they’ve already taken a dose. Caregivers trusting labels alone are making decisions with incomplete information. The solution is to shift from label-reading to healthcare partnership.
Before starting any supplement, caregivers should have a detailed conversation with the person’s doctor or pharmacist about that specific supplement, its potential interactions, its unproven status for cognitive health, and safer alternatives. This conversation should happen before the supplement is purchased, not after. Caregivers should also ask whether the healthcare provider recommends the supplement based on current evidence, which for most cognitive supplements is: no evidence at all. The label won’t ask these questions. The caregiver has to.
You Might Also Like
- What Caregivers Should Know About Sleep and Dementia Symptoms
- What Caregivers Should Ask About Nutrition in Dementia Care
- Why Supplement Warnings Matter in Dementia Prevention
Related reading
- what CNS Models Reveal About Therapeutic Efficacy
- could Better Lab Models Reduce Failed Alzheimer’s Trials
- why Drug Testing Needs More Realistic Alzheimer’s Models
- how Researchers Build Alzheimer’s Disease in a Dish
- can Artificial Brain Models Replace Some Animal Studies
For more on this topic, see National Institute on Aging.
